Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Key biomarkers identified for predicting disability progression in multiple sclerosis
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS). The breakthrough research has the potential to transform treatment strategies for millions of MS patients worldwide,
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi’s eyes approval after MS therapy slows disease progression by 31%
After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.
Multiple Sclerosis News Today11h
Learning to embrace a diagnosis of MS as part of my identity
Columnist Desiree Lama has accepted her MS diagnosis as part of her identity — but it's not the only thing that defines her, ...
MedPage Today1d
Women With MS Less Likely to Receive Treatment Than Men
Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...
PHILADELPHIA.Today on MSN2d
Local Multiple Sclerosis Advocate Honored With State Citation
Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...
Multiple Sclerosis News Today11h
ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...
Medpage Today on MSN5d
Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse Outcomes
Higher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...
Medscape10d
Does Multiple Sclerosis Protect Against Alzheimer's?
Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...
Neurology Advisor2h
Gaps in Access to Care Persist for Patients With MS, Affect HRQOL
Gaps in access to care persist for US patients with MS and impact HRQOL to a large extent. Improving access to care for patients with MS should be prioritized.
FierceBiotech3d
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
Stories on US FDA approving injectable Roche multiple sclerosis therapy are withdrawn
The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...
BioTechniques3d
Biomarkers for predicting multiple sclerosis progression identified
Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - ...